Is TLIS undervalued or overvalued?
As of 2025-03-20, the Intrinsic Value of Talis Biomedical Corp (TLIS) is 1.85 USD. This TLIS valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 4.38 USD, the upside of Talis Biomedical Corp is -57.80%. This means that TLIS is overvalued by 57.80%.
The range of the Intrinsic Value is 2.06 - 1.71 USD
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (45.28) - 1.48 | (1.61) | -136.8% |
| DCF (Growth 10y) | 1.11 - (46.07) | (2.02) | -146.1% |
| DCF (EBITDA 5y) | 2.06 - 1.71 | 1.85 | -57.8% |
| DCF (EBITDA 10y) | 1.71 - 1.12 | 1.39 | -68.2% |
| Fair Value | -22.04 - -22.04 | -22.04 | -603.23% |
| P/E | (114.00) - (110.82) | (89.38) | -2140.6% |
| EV/EBITDA | (56.50) - 5.59 | (26.68) | -709.0% |
| EPV | (114.50) - (152.58) | (133.54) | -3148.9% |
| DDM - Stable | (47.99) - (260.75) | (154.37) | -3624.4% |
| DDM - Multi | (1.74) - (7.57) | (2.86) | -165.2% |
| Market Cap (mil) | 50.70 |
| Beta | 2.27 |
| Outstanding shares (mil) | 11.58 |
| Enterprise Value (mil) | -9.17 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.83% |
| Cost of Debt | 5.00% |
| WACC | 5.75% |